223 related articles for article (PubMed ID: 24033863)
1. Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy--a combined analysis of 713 type 2 diabetic patients.
Seufert J; Brath H; Pscherer S; Borck A; Bramlage P; Siegmund T
Diabetes Obes Metab; 2014 Mar; 16(3):248-54. PubMed ID: 24033863
[TBL] [Abstract][Full Text] [Related]
2. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
4. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials.
Lankisch MR; Del Prato S; Dain MP; Mullins P; Owens DR
Prim Care Diabetes; 2016 Feb; 10(1):51-9. PubMed ID: 26150328
[TBL] [Abstract][Full Text] [Related]
5. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.
Dailey GE; Gao L; Aurand L; Garg SK
Diabetes Obes Metab; 2013 Dec; 15(12):1085-92. PubMed ID: 23683002
[TBL] [Abstract][Full Text] [Related]
6. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
[TBL] [Abstract][Full Text] [Related]
8. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
9. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
10. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
11. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study.
Fritsche A; Larbig M; Owens D; Häring HU;
Diabetes Obes Metab; 2010 Feb; 12(2):115-23. PubMed ID: 20092584
[TBL] [Abstract][Full Text] [Related]
12. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies.
Riddle MC; Vlajnic A; Zhou R; Rosenstock J
Diabetes Obes Metab; 2013 Sep; 15(9):819-25. PubMed ID: 23489438
[TBL] [Abstract][Full Text] [Related]
13. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
14. Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
Rosenstock J; Marre M; Qu Y; Zhang S; Bastyr EJ; Prince MJ; Chang AM
Diabetes Obes Metab; 2016 Nov; 18(11):1093-1097. PubMed ID: 27484021
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):627-33. PubMed ID: 18058596
[TBL] [Abstract][Full Text] [Related]
16. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
17. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
[TBL] [Abstract][Full Text] [Related]
18. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
20. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
